Anetumab-MMAE is an antibody-drug conjugate (ADC) (Anetumab antibody (HY-P99352), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is an anti-mesothelin (MSLN) antibody.

BX-513 hydrochloride inhibits MIP-1α-induced intracellular calcium mobilization (IC50 = 2.5 μM).

Sivelestat(ONO5046; LY544349; EI546) is a competitive inhibitor of human neutrophil elastase(IC50 = 44 nM; Ki=200 nM); also inhibited leukocyte elastase obtained from rabbit, rat, hamster and mouse.

A potent, specific and competitive inhibitor of human neutrophil elastase with IC50 of 44 nM.

SKPer1 (XMU-MP-8) is a small-molecule degrader of SKP2 that triggers degradation of the oncoprotein SKP2 and specifically kills SKP2-expressing cancer cells.

Telisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) composed of the anti–c-Met humanized monoclonal antibody coupled to the cytotoxic monomethyl auristatin E (MMAE) through a mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for research on advanced solid tumours.

Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate (ADC) composed of an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody and a anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE).

Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.

Farletuzumab-MMAE is an antibody-drug conjugate (ADC) composed of humanized anti-human folate receptor-alpha (FRα) and the cytotoxic agent monomethyl auristatin (MMAE) via a MC-Vc linker. It has a potent antitumor activity.

Trastuzumab vedotin (MRG002) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab vedotin is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab vedotin can be used for the research of HER2-positive breast cancer.

Cetuximab-MMAE is an antibody-drug conjugate composed of a anti-EGFR monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker.

Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer.

Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL).

KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity.

3-Epideoxycholic acid is the microbial metabolite of Deoxycholic acid. 3-Epideoxycholic acid targets FXR of dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exhibits anti-inflammatory activity. 3-Epideoxycholic acid promotes the growth of bacteria Bacteroides.